Dudediligence.

Aquestive Therapeutics, Inc

AQSTNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$13.5MSep ’24$11.9MDec ’24$8.7MMar ’25$10.0MJun ’25$12.8MSep ’25$13.0MDec ’25$14.4MMar ’26$13.8MJun ’26
Net income, by quarter
−$11.5MSep ’24−$17.1MDec ’24−$22.9MMar ’25−$13.5MJun ’25−$15.4MSep ’25−$31.9MDec ’25−$8.1MMar ’26−$22.9MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$50.8M$47.7M$50.6M$57.6M$44.5M
Gross profitnone on file$28.3M$29.8M$39.7M$26.0M
Operating income−$34.7M−$42.1M−$15.1M−$30.8M−$71.1M
Net income−$70.5M−$54.4M−$7.9M−$44.1M−$83.8M
Operating cash flow−$33.0M−$9.8M−$6.4M−$35.8M−$52.4M
Free cash flow−$33.9M−$10.8M−$7.4M−$35.9M−$53.0M
Cash$28.0M$27.3M$23.9M$71.5M$121.2M
Debtnone on file$33.4M$27.5M$32.5M$55.0M
Shares outstanding41.2M54.8M68.5M91.4M122.0M